GNRRF News and Press, GeNeuro SA

Partnership to combine GeNeuro’s expertise in HERVs with Verily’s Immune Profiler and Workbench platforms to investigate biomarkers related to HERV-W GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerativ...

GeNeuro press release ( OTC:GNRRF ): Q3 at September 30, 2022,  it had €9.6M in cash. As announced in the interim financial report for the six months ended June 30, 2022, the available cash resources provide GeNeuro with financial visibility until end of 2023, cove...

GeNeuro press release ( OTC:GNRRF ): Q2 at June 30, 2022, GeNeuro had €10M in cash. The total available cash resources provide GeNeuro with visibility until Q2 2023 in terms of financing all its current activities. For further details see: GeNeuro reports Q2 r...